Spotlight On... Sensus squeaks out with $11M IPO for low-energy x-ray treatment; University of Missouri studies show monitoring walking speed and heart health can maintain older adult health; and more...

Sensus Healthcare ($SRTSU) raised $11 million by selling 2 million units at $5.50. That was after the company had reduced its proposed price of $6.25. This is the third med tech IPO in the U.S. this week; Clearside Biomedical ($CLSD) similarly had to reduce its price ahead of the IPO but traded up in its first day. Sensus was also gaining ground in early trading--up 7% in early trading to $5.90. The company offers superficial radiation treatment devices for non-melanoma skin cancer and keloids with installations in more than 220 locations. More

> Waltham, MA-based wearables and point-of-care test maker Neurometrix ($NURO) announced it has entered into a definitive securities purchase agreement totaling $21.3 million. Release

> University of Missouri researchers reported data from studies that demonstrate how monitoring walking speed using radar and heart health using bed sensors can help maintain older adults' health. Release

> Provision Asia and Shenzhen Hairong International Medical Development Co. formed a joint venture, Provision Asia, which will develop cancer centers and proton therapy centers in China. It will also distribute Proton Therapy Systems developed by Provision Healthcare in China. Release

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.